{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:56:25Z","timestamp":1789376185484,"version":"build-2803163510"},"reference-count":0,"publisher":"Portland Press Ltd.","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1995,11,1]]},"abstract":"<jats:p>Reactive metabolites are believed to be responsible for many types of toxicity, including idiosyncratic drug reactions. Bone marrow is a frequent target of idiosyncratic reactions, and, since these reactions have characteristics that suggest involvement of the immune system, the formation of reactive metabolites by leucocytes could also play a role in the aetiology of idiosyncratic drug reactions. The major oxidation system in neutrophils and monocytes is a combination of NADPH oxidase and myeloperoxidase. This system oxidizes primary arylamines, such as sulphonamides, to reactive metabolites and these drugs are also associated with a high incidence of agranulocytosis, generalized idiosyncratic reactions and\/ or drug-induced lupus. Clozapine is oxidized by this system to a relatively stable nitrenium ion; clozapine is also associated with a high incidence of agranulocytosis. Arylamines that have an oxygen or nitrogen in the para position, such as amodiaquine, vesnarinone and 5-aminosalicylic acid, are oxidized to quinone-like reactive intermediates. Aminopyrine is oxidized to a very reactive dication. Such reactive metabolites could also inhibit neutrophil function and mediate some of the therapeutic effects of these drugs: for example, the use of dapsone for dermatitis herpetiformis and the use of 5-aminosalicylic acid for inflammatory bowel disease.<\/jats:p>","DOI":"10.1042\/bss0610163","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T19:13:19Z","timestamp":1439233999000},"page":"163-170","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Myeloperoxidase as a generator of drug free radicals"],"prefix":"10.1042","volume":"61","author":[{"given":"Jack P.","family":"Uetrecht","sequence":"additional","affiliation":[{"name":"Faculties of Pharmacy and Medicine, Drug Safety Research Group, University of Toronto and Sunnybrook Health Science Centre, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","container-title":["Biochemical Society Symposia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemsocsymp\/article-pdf\/doi\/10.1042\/bss0610163\/837501\/bss0610163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemsocsymp\/article-pdf\/doi\/10.1042\/bss0610163\/837501\/bss0610163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T08:21:09Z","timestamp":1637050869000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemsocsymp\/article\/doi\/10.1042\/bss0610163\/50020\/Myeloperoxidase-as-a-generator-of-drug-free"}},"subtitle":[],"editor":[{"given":"C.","family":"Rice-Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"B.","family":"Halliwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"G.G.","family":"Lunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[1995,11,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1042\/bss0610163","relation":{},"ISSN":["0067-8694","1744-1439"],"issn-type":[{"value":"0067-8694","type":"print"},{"value":"1744-1439","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,11,1]]}}}